Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission -110% Improvement Relative Risk Oxygen therapy -110% Hospitalization time -36% Recovery, dyspnea -33% Recovery, fever -75% Recovery, lymphopenia -92% Recovery, cough -70% c19early.org/ace Sobhy et al. PACTR202202880140319 Acetaminophen RCT LATE Is late treatment with acetaminophen beneficial for COVID-19? Double-blind RCT 180 patients in Egypt (January - May 2022) Trial compares with ibuprofen, results vs. placebo may differ Higher ICU admission (p=0.047) and higher need for oxygen therapy (p=0.047) Sobhy et al., The Open Anesthesia J., doi:10.2174/25896458-v17-e230403-2022-26 Favors acetaminophen Favors ibuprofen

Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial

Sobhy et al., The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26, PACTR202202880140319
Sobhy et al., Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of.., The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26, PACTR202202880140319
Apr 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 180 moderate hospitalized COVID-19 patients in Egypt, showing higher ICU admission and longer hospitalization with acetaminophen compared with ibuprofen. Acetaminophen is also known as paracetamol.
This study includes acetaminophen and ibuprofen.
risk of ICU admission, 110.0% higher, RR 2.10, p = 0.047, treatment 21 of 90 (23.3%), control 10 of 90 (11.1%).
risk of oxygen therapy, 110.0% higher, RR 2.10, p = 0.047, treatment 21 of 90 (23.3%), control 10 of 90 (11.1%).
hospitalization time, 35.7% higher, relative time 1.36, p = 0.01, treatment 90, control 90.
risk of no recovery, 33.3% higher, RR 1.33, p = 1.00, treatment 4 of 90 (4.4%), control 3 of 90 (3.3%), day 4, dyspnea.
risk of no recovery, 75.0% higher, RR 1.75, p = 0.25, treatment 14 of 90 (15.6%), control 8 of 90 (8.9%), day 4, fever.
risk of no recovery, 92.3% higher, RR 1.92, p = 0.04, treatment 25 of 90 (27.8%), control 13 of 90 (14.4%), day 4, lymphopenia.
risk of no recovery, 70.0% higher, RR 1.70, p = 0.03, treatment 34 of 90 (37.8%), control 20 of 90 (22.2%), day 4, cough.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sobhy et al., 19 Apr 2023, Double Blind Randomized Controlled Trial, Egypt, peer-reviewed, 6 authors, study period January 2022 - May 2022, this trial compares with another treatment - results may be better when compared to placebo, trial PACTR202202880140319.
Contact: dr.amrsobhy2013@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: 1874-3218/23 Send Orders for Reprints to reprints@benthamscience.net 1 The Open Anesthesia Journal Content list available at: https://openanesthesiajournal.com CLINICAL TRIAL STUDY Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial Amr Sobhy1,*, Lobna A. Saleh2, Marwa E.l AbdelAtty3, Ahmed M. AbdElmaksoud1, Sameh A. Refaat1 and Mohammed Kamal1 1 Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt Department of Clinical Pharmacology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt 3 Department of Chest, Giza Chest Hospital, Cairo, Egypt 2 Abstract:
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit